Nine Bridges Capital Valuation Services
Nine Bridges Capital has expertise in many valuation methodologies, including but not limited to discounted cash flow (DCF), probability adjusted DCF (for pharma/biotech), relative valuation and venture capital valuation. In most cases DCF is the cornerstone of the valuation process, while relative valuation models and venture capital valuation models are used to provide insight into what the public markets, potential acquirors or venture capitalists are willing to pay for similar assets. When performed in combination, these valuation methodologies will provide you with a reasonable valuation range for your specific business situation. The insight provided by a Nine Bridges Capital valuation will put you in a more informed decision-making and negotiating position.
Probability adjusted DCF for Pharma/Biotech companies involved in drug development is the industry standard. It is used by virtually all international pharma/biotech companies. Using our knowledge of probabilities of technical success in various therapeutic areas as well as our knowledge of international and domestic pharmaceuticals markets, Nine Bridges Capital will develop an accurate valuation model for your or your potential partner’s drug development portfolio and will therefore prepare you for your partnership (M&A, in-licensing, out-licensing, JVs, etc.) negotiations. We highly recommend that you not enter into any partnership negotiation without understanding the value of the drug candidate(s) in your and/or your partner’s portfolio in all possible target markets. A properly constructed valuation model from Nine Bridges Capital is a tool that you can use throughout the negotiation process to ensure that you either bid/receive fair value for your partner’s/your portfolio under any deal structure, whether in-licensing out-licensing, selling or acquiring.
Tags: Business, Partnership, Valuation Service